Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1- mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease

Blood (2024) 144 (Supplement 1): 4336.

https://doi.org/10.1182/blood-2024-209462

Published: 2024

Journal Articles

Does Detection of <20% Lymphoblasts in Patients with CML Herald Imminent Blast Crisis? a Study from BCR::ABL1 Pathology Group

Blood (2023) 142 (Supplement 1): 6364.

https://doi.org/10.1182/blood-2023-187020

Published: 2023

Journal Articles

Optical Genomic Mapping Provides Unique Findings in Various Types of Myeloid Neoplasms

Andres E Quesada, Gokce A. Toruner, Zhenya Tang, Shimin Hu, Jie Xu, Shaoying Li, Farhad Ravandi, Hagop M. Kantarjian, M. James You, L. Jeffrey Medeiros, Guilin Tang

Blood (2023) 142 (Supplement 1): 4303.

https://doi.org/10.1182/blood-2023-177803

Published: 2023

Journal Articles

EBV + ALK + large B-cell lymphoma

Hui Liu, Shimin Hu

Blood (2021) 138 (25): 2741.

https://doi.org/10.1182/blood.2021013595

Published: 2021

Journal Articles

Acute leukemic variant of blastic plasmacytoid dendritic cell neoplasm at initial presentation

Hui Liu, Shimin Hu

Blood (2020) 135 (17): 1506.

https://doi.org/10.1182/blood.2020005039

Published: 2020

Journal Articles

Coactivation of NF-κB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion

Blood (2020) 135 (2): 108–120.

https://doi.org/10.1182/blood.2019001438

Published: 2020

Includes: Supplemental data

Journal Articles

Characteristics, Treatments, and Outcomes of Patients with Lymphomatoid Granulomatosis—MD Anderson Cancer Center Experience

Preetesh Jain, MBBS,MDDM,PhD, Rashmi Kanagal-Shamanna, MD, Ahmad Ghorab, MDMSc, Loretta Nastoupil, MD, Luis E. Fayad, Jeffrey Medeiros, MD, Shimin Hu, Sattva S. Neelapu, MD, Jason R. Westin, MD, Yasuhiro Oki, MD, Michael Wang, MD, Nathan H. Fowler, MD

Blood (2017) 130 (Supplement 1): 2852.

https://doi.org/10.1182/blood.V130.Suppl_1.2852.2852

Published: 2017

Journal Articles

Impact of I(17q) in Myeloproliferative Neoplasms

Zimu Gong, MD, Zi Chen, MD, Srdan Verstovsek, MD PhD, Jorge E. Cortes, MD, Arash Ronaghy, MD, Wei Wang, MD PhD, Carlos E. Bueso-Ramos, MD PhD, L. Jeffrey Medeiros, MD, Shimin Hu, PhD MD

Blood (2017) 130 (Supplement 1): 2911.

https://doi.org/10.1182/blood.V130.Suppl_1.2911.2911

Published: 2017

Journal Articles

Cytogenetics-Based Risk Prediction of Blastic Transformation of CML Treated with Tyrosine Kinase Inhibitors

Zimu Gong, MD, L. Jeffrey Medeiros, MD, Jorge E. Cortes, MD, Wei Wang, MD PhD, Hagop M. Kantarjian, MD, Shimin Hu

Blood (2017) 130 (Supplement 1): 247.

https://doi.org/10.1182/blood.V130.Suppl_1.247.247

Published: 2017

Journal Articles

Philadelphia chromosome–positive B-lymphoblastic lymphoma involving the genitourinary system and bone at initial diagnosis and relapse

Lan Zheng, Shimin Hu

Blood (2017) 130 (12): 1483.

https://doi.org/10.1182/blood-2017-05-785626

Published: 2017

Journal Articles

Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients

Blood (2016) 128 (22): 1220.

https://doi.org/10.1182/blood.V128.22.1220.1220

Published: 2016

Journal Articles

Mixed Phenotype Blast Phase of Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitor Therapy

Zimu Gong, Shi Bai, Shimin Hu

Blood (2016) 128 (22): 5438.

https://doi.org/10.1182/blood.V128.22.5438.5438

Published: 2016

Journal Articles

Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

Wei Wang, Jorge E. Cortes, Guilin Tang, Joseph D. Khoury, Sa Wang, Carlos E. Bueso-Ramos, Joseph A. DiGiuseppe, Zi Chen, Hagop M. Kantarjian, L. Jeffrey Medeiros, Shimin Hu

Blood (2016) 127 (22): 2742–2750.

https://doi.org/10.1182/blood-2016-01-690230

Published: 2016

Includes: Supplemental data

Journal Articles

MYC / BCL2 double-hit lymphoma/leukemia mimicking acute leukemia at initial presentation

Zi Chen, Shimin Hu

Blood (2016) 127 (8): 1072.

https://doi.org/10.1182/blood-2015-11-683730

Published: 2016

Journal Articles

Preclinical Evaluation of the Oral Proteasome Inhibitor Ixazomib in Diffuse Large B-Cell Lymphoma

Wei Liu, MD, Archie Tamayo, MS, Juan Chen, PhD, Shimin Hu, PhD MD, Richard J. Ford, Jr., MD PhD, Lan Pham, PhD

Blood (2015) 126 (23): 4003.

https://doi.org/10.1182/blood.V126.23.4003.4003

Published: 2015

Journal Articles

Clinico-Pathological Characteristics, Treatments and Outcomes of Patients with Dendritic Cell Sarcoma (DS)

Preetesh Jain, MBBS,MDDM,PhD, Keyur P. Patel, MD PhD, Andrew Futreal, PhD, Curtis Gumbs, Shimin Hu, PhD MD, Carlos Bueso Ramos, MD, Michael Wang, MD, Jorge Romaguera, Luis E. Fayad, MD, Robert Z. Orlowski, PhD, MD, Jeffrey Medeiros, Nathan Fowler, MD

Blood (2015) 126 (23): 2700.

https://doi.org/10.1182/blood.V126.23.2700.2700

Published: 2015

Journal Articles

Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors

Wei Wang, Jorge E. Cortes, Pei Lin, Michael W. Beaty, Di Ai, Hesham M. Amin, Timothy J. McDonnell, Chi Young Ok, Hagop M. Kantarjian, L. Jeffrey Medeiros, Shimin Hu

Blood (2015) 126 (14): 1699–1706.

https://doi.org/10.1182/blood-2015-05-646489

Published: 2015

Includes: Supplemental data

Journal Articles

Neoplastic plasma cells mimic mature neutrophils in plasma cell myeloma with t(11;14)(q13;q32)

Wei Wang, Shimin Hu

Blood (2015) 125 (18): 2875.

https://doi.org/10.1182/blood-2014-12-617795

Published: 2015

Journal Articles

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

Blood (2013) 121 (20): 4021–4031.

https://doi.org/10.1182/blood-2012-10-460063

Published: 2013

Includes: Supplemental data

Journal Articles

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

Blood (2013) 121 (14): 2715–2724.

https://doi.org/10.1182/blood-2012-10-461848

Published: 2013

Includes: Supplemental data

NARROW

Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1- mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease

Does Detection of <20% Lymphoblasts in Patients with CML Herald Imminent Blast Crisis? a Study from BCR::ABL1 Pathology Group

Optical Genomic Mapping Provides Unique Findings in Various Types of Myeloid Neoplasms

EBV + ALK + large B-cell lymphoma

Acute leukemic variant of blastic plasmacytoid dendritic cell neoplasm at initial presentation

Coactivation of NF-κB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion

Characteristics, Treatments, and Outcomes of Patients with Lymphomatoid Granulomatosis—MD Anderson Cancer Center Experience

Impact of I(17q) in Myeloproliferative Neoplasms

Cytogenetics-Based Risk Prediction of Blastic Transformation of CML Treated with Tyrosine Kinase Inhibitors

Philadelphia chromosome–positive B-lymphoblastic lymphoma involving the genitourinary system and bone at initial diagnosis and relapse

Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients

Mixed Phenotype Blast Phase of Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitor Therapy

Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

MYC / BCL2 double-hit lymphoma/leukemia mimicking acute leukemia at initial presentation

Preclinical Evaluation of the Oral Proteasome Inhibitor Ixazomib in Diffuse Large B-Cell Lymphoma

Clinico-Pathological Characteristics, Treatments and Outcomes of Patients with Dendritic Cell Sarcoma (DS)

Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors

Neoplastic plasma cells mimic mature neutrophils in plasma cell myeloma with t(11;14)(q13;q32)

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only